CLINICAL_TRIALS
trial_result
· 2018-05-09
Clinical Trial Update: A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML [Phase 1]
Summary
A completed Phase 1 safety study evaluating SGN-CD33A in combination with standard-of-care in patients with acute myeloid leukemia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Seagen Inc. | Conditions: Acute Myeloid Leukemia, Acute Myelogenous Leukemia | Phase 1 | Status: COMPLETED